Therapies for narcolepsy with or without cataplexy: Evidence-based review

Current Opinion in Neurology

Volumn 20, Issue 6, 2007, Pages 699-703

  Keam, Susan ^a   Walker, Matthew C ^b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AMPHETAMINE; ANTIDEPRESSANT AGENT; ARMODAFINIL; ATOMOXETINE; ESCITALOPRAM; METHYLPHENIDATE; MODAFINIL; OXYBATE SODIUM; PLACEBO; REBOXETINE; RITANSERIN;

CATAPLEXY; CLINICAL TRIAL; DAYTIME SOMNOLENCE; DIZZINESS; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; ENURESIS; EVIDENCE BASED MEDICINE; HUMAN; MONOTHERAPY; NARCOLEPSY; NAUSEA; OUTCOME ASSESSMENT; REVIEW; SYMPTOM; THERAPY EFFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING;

CENTRAL NERVOUS SYSTEM STIMULANTS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; HUMANS; NARCOLEPSY; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 36049049735     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3282f22ad9     Document Type: Review

References (35)

1. Billiard M, Bassetti C, Dauvilliers Y, et al. EFNS guidelines on management of narcolepsy. European Journal of Neurology 2006; 13:1035-1048.
2. Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet 2007; 369:499-511.
3. American Academy of Sleep Medicine. ICSD-2-International Classification of Sleep Disorders, 2nd edn. Diagnostic and Coding Manual. Westchester, IL; 2005.
4. Abad VC, Guilleminault C. Emerging drugs for narcolepsy. Expert Opinion on Emerging Drugs 2004; 9:281-291.
5. Robinson DM, Keating GM. Sodium oxybate: a review of its use in the management of narcolepsy. CNS Drugs 2007; 21:337-354.
6. Longstreth WT Jr, Koepsell TD, Ton TG, et al. The epidemiology of narcolepsy. Sleep 2007; 30:13-26.
7. Ervik S, Abdelnoor M, Heier MS, et al. Health-related quality of life in narcolepsy. Acta Neurologica Scandinavica 2006; 114:198-204.
8. Thorpy M. Therapeutic advances in narcolepsy. Sleep Medicine 2007; 8:427-440.
9. Houghton WC, Scammell TE, Thorpy M. Pharmacotherapy for cataplexy. Sleep Medicine Reviews 2004; 8:355-366.
10. Thorpy MJ. Cataplexy associated with narcolepsy: epidemiology, pathophysiology and management. CNS Drugs 2006; 20:43-50.
11. Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 2006; 29:939-946.
12. Harsh JR, Hayduk R, Rosenberg R, et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Current Medical Research & Opinion 2006; 22:761-774.
13. Mayer G. Ritanserin improves sleep quality in narcolepsy. Pharmacopsychiatry 2003; 36:150-155.
14. Rogers AE, Aldrich MS, Lin X. A comparison of three different sleep schedules for reducing daytime sleepiness in narcolepsy. Sleep 2001; 24:385-391.
15. Thorpy MJ, Schwartz JR, Kovacevic-Ristanovic R, Hayduk R. Initiating treatment with modafinil for control of excessive daytime sleepiness in patients switching from methylphenidate: an open-label safety study assessing three strategies. Psychopharmacology 2003; 167:380-385.
16. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 2000; 54:1166-1175.
17. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Annals of Neurology 1998; 43:88-97.
18. US Xyrem Multicenter Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002; 25:42-49.
19. Weaver TE, Cuellar N. A randomized trial evaluating the effectiveness of sodium oxybate therapy on quality of life in narcolepsy. Sleep 2006; 29:1189-1194.
20. Xyrem International Study Group. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. [see comment]. Journal of Clinical Sleep Medicine 2005; 1:391-397.
21. Xyrem International Study Group. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients.[see comment]. Sleep Medicine 2005; 6:415-421.
22. Becker PM, Schwartz JR, Feldman NT, Hughes RJ. Effect of modafinil on fatigue, mood, and health-related quality of life in patients with narcolepsy. Psychopharmacology 2004; 171:133-139.
23. Lankford A. Sodium oxybate significantly improves sleep architecture in patients with narcolepsy [abstract]. Presented at: American Psychiatric Association 158th Annual Meeting; 2005 May 21-26; Atlanta, Georgia; 2005.
24. Larrosa O, de la Llave Y, Bario S, et al. Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study. Sleep 2001; 24:282-285.
25. Schwartz JR, Feldman NT, Fry JM, Harsh J. Efficacy and safety of modafinil for improving daytime wakefulness in patients treated previously with psychostimulants. Sleep Medicine 2003; 4:43-49.
26. Guilleminault C, Aftab FA, Karadeniz D, et al. Problems associated with switch to modafinil - a novel alerting agent in narcolepsy. European Journal of Neurology 2000; 7:381-384.
27. Niederhofer H. Atomoxetine also effective in patients suffering from narcolepsy? Sleep 2005; 28:1189.
28. Sonka K, Kemlink D, Pretl M. Cataplexy treated with escitalopram-clinical experience. Neuroendocrinology Letters 2006; 27:174-176.
29. Vignatelli L, D'Alessandro R, Candelise L. Antidepressant drugs for narcolepsy. Cochrane Database of Systematic Reviews 2005:CD003724
30. Mitler MM, Harsh J, Hirshkowitz M, Guilleminault C. Long-term efficacy and safety of modafinil (PROVIGIL) for the treatment of excessive daytime sleepiness associated with narcolepsy. Sleep Med 2000; 1:231-243.
31. Beusterien KM, Rogers AE, Walsleben JA, et al. Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep 1999; 22:757-765.
32. US Xyrem Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Medicine 2004; 5:119-123.
33. Anonymous. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 2003; 26:31-35.
34. Jasinski DR, Kovacevi-Ristanovi R. Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy. Clinical Neuropharmacology 2000; 23:149-156.
35. Fuller DE, Hornfeldt CS, Kelloway JS, et al. The Xyrem risk management program. Drug Safety 2004; 27:293-306.